Overview
Saxenda is Novo Nordisk’s brand of liraglutide at the 3 mg dose, and it was the medication that opened this category. Approved by the FDA in December 2014 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, it was later approved for patients aged 12 and older — a distinction that still matters, because paediatric approvals in this class are limited.
Two developments have changed what Saxenda means in 2026. First, Novo Nordisk has provided advance notice that it will discontinue Saxenda, with last shipments to wholesalers taking place in late January 2027. Patients currently on brand-name Saxenda need a transition plan, not a wait-and-see approach.
Second, in August 2025 the FDA approved the first generic liraglutide injection for long-term weight management in adults with obesity, or overweight with weight-related conditions. The generic works the same way as the brand. That approval is what makes the discontinuation manageable rather than a crisis — but it does mean patients will need to move to a different product.
On price, Saxenda has always been expensive. Novo Nordisk publishes a list price of $1,349.02 for a five-pen package, with savings programmes under which some eligible patients pay as little as $25 or save up to $200 per prescription for up to twelve months. Generic liraglutide has been listed at figures in the range of roughly $1,084 for a comparable quantity, so the generic is cheaper but has not yet collapsed the price the way generics often do. Clinically, liraglutide generally produces less weight loss than weekly semaglutide or tirzepatide — which is the honest reason most of the market moved on.
What Makes Saxenda Different
The Original Approved Weight-Management GLP-1
Approved in December 2014, Saxenda established the regulatory pathway that Wegovy and Zepbound later followed. It has more than a decade of real-world use behind it, which is a longer safety record than any newer agent in this class.
Approved Down to Age 12
The FDA extended Saxenda’s approval to patients aged 12 and older for weight management. Paediatric approvals in this class remain limited, and for adolescent patients this is a meaningful distinction rather than a technicality.
Being Discontinued in Early 2027
Novo Nordisk has given advance notice of discontinuation, with last shipments to wholesalers in late January 2027. If you are currently on brand-name Saxenda, this is a planning matter for now rather than an emergency — but it is a planning matter you should not defer.
A Generic Now Exists
The FDA approved the first generic liraglutide injection for long-term weight management in August 2025. It works the same way as the brand. That is the natural landing place for most patients affected by the discontinuation.
✓ Pros
- •FDA-approved since December 2014 — a decade-plus of real-world safety data
- •Approved for patients aged 12 and older — rare in this medication class
- •A generic is now approved — providing continuity after discontinuation
- •Full FDA review — safety, efficacy and manufacturing quality assessed, unlike compounded products
- •Manufacturer savings programme — eligible patients may pay as little as $25 or save up to $200 per prescription
- •An option when weekly agents are unsuitable — a genuine alternative for some patients
- •Daily dosing allows finer titration — some patients tolerate gradual daily escalation better
✗ Cons
- •Being discontinued — last shipments to wholesalers in late January 2027
- •Once-daily injection — seven injections a week rather than one
- •Generally less weight loss than semaglutide or tirzepatide — the main reason the market moved on
- •High list price — $1,349.02 for a five-pen package
- •Generic pricing has not collapsed — listed around $1,084 for a comparable quantity
- •Savings programme is time-limited — described as up to twelve months for eligible patients
- •Insurance coverage for weight management is inconsistent — and Medicare Part D generally excludes weight-loss indications
- •Boxed warning for thyroid C-cell tumors — as with all GLP-1 receptor agonists in this class
Our #1 Recommended Provider
If you are on Saxenda and planning your transition, or considering liraglutide for the first time, it is worth pricing the weekly agents too. Coreage RX offers compounded semaglutide and tirzepatide at a flat $99 per month.
Medications Offered
Brand-Name or Compounded?
Brand-name, FDA-approved — and being withdrawn. Saxenda is liraglutide 3 mg, approved by the FDA for chronic weight management in December 2014 and later extended to patients aged 12 and older. Novo Nordisk has given advance notice of discontinuation with last shipments to wholesalers in late January 2027. A generic liraglutide injection was approved by the FDA in August 2025 and works the same way.
Saxenda (liraglutide 3 mg)
List price $1,349.02 per five-pen packageA once-daily subcutaneous injection titrated gradually to the 3 mg maintenance dose. Novo Nordisk states eligible patients may pay as little as $25 or save up to $200 per prescription for up to twelve months through its savings programme. Being discontinued with last wholesaler shipments in late January 2027.
Generic Liraglutide Injection
Listed around $1,084 for a comparable quantityApproved by the FDA in August 2025 as the first generic liraglutide for long-term weight management in adults with obesity or overweight with weight-related conditions. It works the same way as the brand. This is the natural continuity option for patients affected by the Saxenda discontinuation.
Victoza (liraglutide 1.8 mg)
Listed around $543.51The same molecule at a lower dose, approved for type 2 diabetes rather than weight management. Some telehealth providers, including Nurx, still list it. It is not the weight-management indication, and prescribing decisions here belong to your clinician.
If you are currently taking Saxenda, the practical question is not whether to switch but to what. Discuss three options with your clinician: generic liraglutide for continuity on the same molecule, a weekly agent such as semaglutide or tirzepatide for greater average weight loss, or a non-GLP-1 option if GLP-1 tolerability has been the problem.
Pricing, Membership & Medication Fees
| Cost Item | What You Pay |
|---|---|
| Saxenda list price | $1,349.02 for a five-pen package, per Novo Nordisk |
| Novo Nordisk savings programme | Eligible patients may pay as little as $25, or save up to $200 per prescription, for up to twelve months |
| Generic liraglutide | Listed around $1,084 for a comparable quantity |
| Victoza (liraglutide 1.8 mg, diabetes indication) | Listed around $543.51 |
| Retail pricing checks | Independent pharmacy checks have reported average retail prices around $1,395 |
| Discontinuation | Last shipments to wholesalers in late January 2027 |
| Insurance | Coverage for weight management is inconsistent; Medicare Part D generally excludes weight-loss indications |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible; confirm with your plan administrator |
The generic is cheaper than the brand but has not delivered the price collapse patients often expect from a generic approval. At roughly $1,084 against a $1,349.02 list price, liraglutide remains an expensive route unless insurance covers it or a savings programme applies to you.
How Saxenda Works
If You Are on Saxenda, Start the Transition Conversation Now
Novo Nordisk has given advance notice that last shipments to wholesalers occur in late January 2027. That is a planning window, not an emergency — but planning windows close. Raise it with your prescriber at your next appointment rather than waiting for a pharmacy to tell you.
Understand How Liraglutide Differs From Weekly Agents
Liraglutide is injected once daily and generally produces less weight loss than once-weekly semaglutide or tirzepatide. If it was chosen for you because of tolerability, cost or a specific clinical reason, that reason still applies. If it was simply what was available, revisit the choice.
Titrate Gradually
Saxenda is titrated upward over several weeks to the 3 mg maintenance dose to manage gastrointestinal side effects. Daily dosing allows finer control of that escalation than weekly agents, which some patients tolerate better.
Check Whether a Savings Programme Applies
Novo Nordisk states eligible patients may pay as little as $25 or save up to $200 per prescription for up to twelve months. Eligibility rules apply and the programme is time-limited — check the terms rather than assuming.
Compare the Generic Before Assuming It Is Cheap
Generic liraglutide has been approved since August 2025 and works the same way as the brand, but listed around $1,084 it is not dramatically cheaper. Price it at your own pharmacy alongside your other options rather than assuming a generic means a low price.
Store and Handle Correctly
Liraglutide pens are temperature-sensitive and require refrigeration before first use. Follow the dispensing instructions on in-use storage and disposal, and never share a pen or needle between people.
Program Details at a Glance
| Detail | Saxenda |
|---|---|
| Medication class | GLP-1 receptor agonist. Liraglutide 3 mg, administered by once-daily subcutaneous injection. |
| Approval status | FDA-approved for chronic weight management since December 2014, and subsequently approved for patients aged 12 and older. |
| Eligibility | Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, per the approved indication. Prescribing decisions rest with your clinician. |
| Provider involvement | Prescription-only. Requires a prescribing clinician and, in practice, ongoing follow-up during titration. |
| Lab requirements | Determined by your clinician based on your history and comorbidities. |
| Pharmacy fulfillment | Dispensed through standard retail and mail-order pharmacy channels as an FDA-approved product, not through compounding pharmacies. |
| Dosing frequency | Once daily, titrated gradually to the 3 mg maintenance dose. |
| Support services | Novo Nordisk operates patient support and savings programmes; check current eligibility terms directly. |
| Membership fee | Not applicable — this is a medication, not a programme. Any membership fee depends on the provider you obtain it through. |
| Medication fee | List price $1,349.02 for a five-pen package. Generic liraglutide listed around $1,084 for a comparable quantity. |
| Cancellation policy | Not applicable to the medication itself. Never stop a GLP-1 abruptly without discussing it with your clinician. |
| Refund policy | Not applicable. Dispensed prescription medication is generally not returnable. |
| Insurance | Coverage for weight-management indications is inconsistent across plans. Medicare Part D generally excludes weight-loss indications. |
| HSA / FSA | Prescription costs are commonly HSA/FSA eligible. Confirm with your plan administrator and keep itemised receipts. |
| Discontinuation | Novo Nordisk has given advance notice of discontinuation, with last shipments to wholesalers in late January 2027. |
Who Saxenda Is Best For
✓ Best For:
- • Patients already established on liraglutide who tolerate it well
- • Adolescent patients aged 12 and older, where approved options are limited
- • Anyone for whom weekly semaglutide or tirzepatide has proved unsuitable
- • Patients who prefer finer daily titration control over weekly dosing
- • People who want a medication with over a decade of real-world safety data
- • Anyone whose insurance covers liraglutide but not the newer weekly agents
✗ Not Best For:
- • Patients seeking maximum weight loss — weekly agents generally outperform liraglutide
- • Anyone who does not want to inject daily
- • Patients starting treatment now who want long-term product continuity from the brand
- • People paying cash without a savings programme or insurance coverage
- • Anyone with a personal or family history of medullary thyroid carcinoma or MEN2
- • Patients who want the lowest available cost for GLP-1 therapy
Limitations to Know Before You Sign Up
- ⚠Novo Nordisk has given advance notice that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027. Patients currently taking it need a transition plan agreed with their clinician.
- ⚠Liraglutide generally produces less weight loss than once-weekly semaglutide or tirzepatide. That difference is the main reason most of the market and most telehealth providers moved to the newer agents.
- ⚠Daily injection is a materially different adherence proposition from weekly dosing — seven injections a week rather than one.
- ⚠The list price of $1,349.02 for a five-pen package is high, and generic liraglutide at around $1,084 has not delivered the price collapse a generic approval often implies.
- ⚠Like all GLP-1 receptor agonists in this class, liraglutide carries a boxed warning regarding thyroid C-cell tumors, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
- ⚠Insurance coverage for weight-management indications is inconsistent, and Medicare Part D generally excludes weight-loss indications — which limits access for many older patients.
Alternatives to Saxenda
Trulicity
Another weekly GLP-1 approved for diabetes rather than weight, with a mean trial weight loss of just 2 to 5 kg.
Wegovy / Ozempic
FDA-approved weekly semaglutide, with substantially greater average weight loss than liraglutide.
Mounjaro / Zepbound
FDA-approved weekly tirzepatide, the dual GLP-1/GIP agonist with the greatest average weight loss of the approved options.
Hone Health
Offers compounded liraglutide from $160/month plus membership, a route to the same molecule after discontinuation.
Contrave
An oral, non-GLP-1 FDA-approved weight-management option at $99/month through the manufacturer programme.
Frequently Asked Questions
Is Saxenda being discontinued?
Yes. Novo Nordisk has provided advance notice that it will discontinue Saxenda, with last shipments to wholesalers taking place in late January 2027. If you are currently taking Saxenda, discuss a transition plan with your prescriber rather than waiting for supply to run out.
Is there a generic version of Saxenda?
Yes. In August 2025 the FDA approved the first generic liraglutide injection for long-term weight management in adults with obesity, or overweight with weight-related conditions. The generic works the same way as the brand and is the natural continuity option for patients affected by the discontinuation.
How much does Saxenda cost?
Novo Nordisk publishes a list price of $1,349.02 for a five-pen package. Its savings programme states eligible patients may pay as little as $25, or save up to $200 per prescription, for up to twelve months. Independent pharmacy checks have reported average retail prices around $1,395. Generic liraglutide has been listed around $1,084 for a comparable quantity.
Is Saxenda as effective as Wegovy or Zepbound?
Generally no. Liraglutide typically produces less weight loss than once-weekly semaglutide (Wegovy) or tirzepatide (Zepbound). It remains a legitimate option for patients the newer agents do not suit, but if maximum weight loss is the goal and the weekly agents are available to you, the comparison favours them.
How often do I inject Saxenda?
Once daily, titrated gradually upward to the 3 mg maintenance dose to manage gastrointestinal side effects. That is seven injections a week, compared with one for semaglutide or tirzepatide — a meaningful difference in adherence terms that is worth considering honestly before starting.
Can teenagers take Saxenda?
The FDA approved Saxenda for weight management in patients aged 12 and older. Paediatric approvals in this class are limited, so this is a genuine distinction. Any decision about GLP-1 therapy in an adolescent belongs entirely with the treating clinician and family.
What are the main risks?
Like all GLP-1 receptor agonists in this class, liraglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Common side effects are gastrointestinal, particularly during titration. Pancreatitis and gallbladder disease are among the serious risks to discuss with your clinician.
What should I switch to when Saxenda is discontinued?
That is a clinical decision, and there are three main directions: generic liraglutide to stay on the same molecule, a weekly agent such as semaglutide or tirzepatide for greater average weight loss, or a non-GLP-1 option such as Contrave or Qsymia if GLP-1 tolerability has been the problem. Raise it with your prescriber well before January 2027.
The Bottom Line
Saxenda earns 3.0 out of 5 stars — a genuinely important medication reaching the end of its commercial life, still clinically legitimate for a narrower group than it once served.
It is easy to underrate Saxenda now that weekly agents dominate the conversation. It was approved in December 2014 and opened the regulatory pathway that Wegovy and Zepbound later walked through. It carries over a decade of real-world safety data, and it is approved for patients aged 12 and older — a distinction that still matters in a class where paediatric approvals are scarce. For patients who tolerate it, or for whom the weekly agents have not worked, liraglutide remains a real option rather than a consolation prize.
But the honest picture in 2026 is one of managed decline. Liraglutide generally produces less weight loss than semaglutide or tirzepatide, it requires seven injections a week rather than one, and Novo Nordisk is discontinuing it with last wholesaler shipments in late January 2027. The August 2025 generic approval makes that transition manageable — but at around $1,084 against a $1,349.02 list price, the generic has not delivered the affordability patients often assume follows a generic approval.
Our recommendation: if you are currently on Saxenda, raise the transition with your prescriber now rather than in late 2026 — generic liraglutide for continuity, a weekly agent for greater weight loss, or a non-GLP-1 option if tolerability has been the issue. If you are starting treatment today, liraglutide is unlikely to be your first choice unless there is a specific clinical reason. Weekly semaglutide and tirzepatide are available at a fraction of this cost through providers such as Coreage RX.
Disclosure:
This review is based on publicly available information including Novo Nordisk’s published Saxenda materials and list price disclosures, the manufacturer’s advance notice of discontinuation, FDA approval and generic approval announcements, and independent pharmacy pricing checks, current as of August 27, 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews; we have no relationship with Novo Nordisk. List prices are not what most patients pay — insurance coverage, manufacturer savings programmes and pharmacy pricing all vary. Discontinuation timelines are as announced by the manufacturer and may change. We do not sell, dispense, or ship medication.
⚕ Medical Disclaimer:
This review is for informational purposes only and is not medical advice, diagnosis, or treatment. Prescription weight-management medications carry serious risks and contraindications; GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. Never start, stop, or change a prescription based on this page. If you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, or other concerning symptoms, seek medical care immediately. See our full medical disclaimer.
Or check out our top-rated provider